There are 2949 resources available
LBA45 - First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)
Presenter: Paolo Ascierto
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA46 - Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
Presenter: Alexander Eggermont
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1076O - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238
Presenter: Jeffrey Weber
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA23 - Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
Presenter: Ajjai Alva
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
697O - A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
Presenter: Thomas Powles
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
CN26 - Patient-reported experiences of cancer care related to the COVID-19 pandemic in Switzerland: A qualitative study
Presenter: Sara Colomer-Lahiguera
Session: EONS13: Oncology care during Covid-19: How does it affect our patients
Resources:
Abstract
Slides
Webcast
LBA24 - TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)
Presenter: Yohann Loriot
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
698O - Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Aristotelis Bamias
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
699O - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers
Presenter: Srikala Sridhar
Session: Proffered Paper - GU, non prostate 1
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA15 and LBA16
Presenter: Lisa Carey
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Slides
Webcast